Nutra Pharma Corp (NPHC) 0.0084 $NPHC Nutra Pharma

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Nutra Pharma Corp (NPHC) 0.0084 $NPHC

Nutra Pharma Letter to Shareholders
Marketwired - Wed Dec 30, 7:30AM CST
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company marketing Nyloxin(R) and Pet Pain-Away in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the Company's Chief Executive Officer, Rik J Deitsch, has published a Shareholder Letter on the Company's website.

Nutra Pharma Corp. (NPHC) CEO Featured in Exclusive QualityStocks Interview
Marketwired - Wed Dec 16, 7:30AM CST
QualityStocks today announces the availability of a new audio interview with Rik Deitsch, CEO of Nutra Pharma Corp. (OTCQB: NPHC), a biotech company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The interview can be heard at http://www.QualityStocks.net/interview-nphc.php.

Nutra Pharma Corp. (NPHC) Announces Engagement of QualityStocks Corporate Communications Suite
Marketwired - Mon Dec 14, 7:30AM CST
Nutra Pharma Corp. (the "Company" (OTCQB: NPHC), a biopharmaceutical company engaged in the acquisition, licensing and marketing of homeopathic treatments and ethical drugs for the management of pain, neurological disorders, cancer, auto-immune and infectious diseases, today announces that it has engaged the Corporate Communications Services of QualityStocks. Based in Scottsdale, Arizona, QualityStocks has assisted more than 300 public companies with their efforts to broaden influence, attract growth capital and improve shareholder value over the past 9 years and 11 months.

Nutra Pharma files for additional orphan drug application with the US FDA for RPI-78M for Myasthenia Gravis
M2 - Thu Dec 10, 5:02AM CST
Biotechnology company Nutra Pharma Corporation (OTCQB:NPHC) disclosed on Wednesday that it has applied for an additional potential orphan drug designation with the US-FDA for its RPI-78M drug candidate for the treatment of Myasthenia Gravis (MG) through the modulation of the immune system, preventing autoimmune effects.

Nutra Pharma Announces Additional Orphan Drug Application for RPI-78M for the Treatment of Myasthenia Gravis
Marketwired - Wed Dec 09, 8:02AM CST
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company marketing Nyloxin(R) and Pet Pain-Away in the over-the-counter (OTC) pain management market, as well as developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have applied for an Orphan Drug designation from the US-FDA for the Company's RPI-78M drug candidate for the treatment of Myasthenia Gravis (MG). On September 8, 2015, the Company announced that they had been granted an Orphan Designation for the treatment of Pediatric Multiple Sclerosis. The designation is designed to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases.

StockNewsNow.com Publishes New SNNLive Video Interview With Nutra Pharma Corporation
Marketwired - Tue Oct 27, 7:31AM CDT
StockNewsNow.com, The Official MicroCap News Source(TM), today published an SNNLive Video Interview with Rik J. Deitsch, CEO of Nutra Pharma Corporation (OTC: NPHC), operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, (see here: www.NutraPharma.com). The video interview was recorded on Wednesday, October 14th, 2015 On-Location in Florida.

Nutra Pharma to Present at Upcoming Investment Conference
Marketwired - Wed Sep 09, 7:30AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company marketing Nyloxin(R) and Pet Pain-Away in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, will be presenting at the upcoming See Thru Equities Conference being held at the Convene Grand Central in New York City on Thursday, September 10th. The presentation will be made by the Company's CEO, Rik J Deitsch, who will be providing updates on the sales and marketing activities for the Company's over-the-counter (OTC) pain relievers, Nyloxin(R) and Pet Pain-Away, as well as discussing the Company's drug product pipeline. This will include a presentation on the designation of Orphan Drug Status for RPI-78M in the treatment of juvenile Multiple Sclerosis (MS).

Nutra Pharma wins US FDA's orphan drug status for RPI-78M for treating juvenile multiple sclerosis
M2 - Wed Sep 09, 3:27AM CDT
Biotechnology company Nutra Pharma (OTC:NPHC) reported on Tuesday ththat it has been given orphan drug designation from the US-FDA for its RPI-78M drug candidate for treating multiple sclerosis in children.

Nutra Pharma's RPI-78M Granted Orphan Drug Status by the US Food and Drug Administration for the Treatment of Juvenile Multiple Sclerosis
Marketwired - Tue Sep 08, 7:30AM CDT
Nutra Pharma Corporation (OTC: NPHC) announced today that they have received Orphan Drug designation from the US-FDA for the Company's RPI-78M drug candidate for the treatment of Multiple Sclerosis in children.

Nutra Pharma Announces the Submission of Their First Orphan Drug Application to the US Food and Drug Administration (FDA)
Marketwired - Wed Jul 15, 7:30AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company marketing Nyloxin(R) and Pet Pain-Away in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have filed an application with the FDA for orphan drug status of the Company's RPI-78M drug candidate for the treatment of Multiple Sclerosis in children.

SeeThruEquity Initiates Coverage on Nutra Pharma Corporation with a Price Target of $0.53
ACCESSWIRE - Fri Jul 10, 8:00AM CDT
NEW YORK, NY / ACCESSWIRE / July 10, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of Nutra Pharma Corporation (OTC: NPHC) with a Price Target of $0.53.

Nutra Pharma Announces Engagement of Investment Banking Firm Pickwick Capital Partners to Provide Strategic Advisory Services
Marketwired - Tue Jun 30, 7:30AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company marketing Nyloxin(R) and Pet Pain-Away in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have engaged Pickwick Capital Partners; a leading investment banking, securities and investment management firm, to provide strategic corporate planning and investment banking services. Pickwick will focus on assisting Nutra Pharma in its strategies for maximizing shareholder value through its full scope of investment banking services.

Nutra Pharma enters into facility and personnel sharing agreement with Nationwide Laboratory Services
M2 - Wed Jun 10, 3:23AM CDT
Biotechnology company Nutra Pharma (OTC:NPHC) revealed on Tuesday the execution of a facility and personnel sharing agreement with Nationwide Laboratory Services.

Nutra Pharma Announces Collaboration With Nationwide Laboratories
Marketwired - Tue Jun 09, 7:31AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company marketing Nyloxin and Pet Pain-Away in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have entered into a facility and personnel sharing agreement with Nationwide Laboratory Services, Inc.

Nutra Pharma Announces Orphan Drug Applications for RPI-78M
Marketwired - Tue May 26, 7:30AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have engaged Medical Strategy Consultants, LLC to aid the company in the filing of Orphan Drug applications with the U.S. Food and Drug Administration ("FDA" . The first application under development is for the treatment of Pediatric Multiple Sclerosis with the Company's lead drug candidate, RPI-78M.

Nutra Pharma Announces Nyloxin(R) Distribution Plans for Canada
Marketwired - Thu May 14, 7:30AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have engaged the Nature's Clinic to begin the process of regulatory approval of the Company's Over-the-Counter pain drug, Nyloxin(R) for marketing and distribution in Canada.

Nutra Pharma Announces Nyloxin(R) Acceptance by Chinese Medical Authority - CPAM
Marketwired - Thu Apr 30, 7:30AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have received notification of the acceptance of Nyloxin(R) by the China International Exchange and Promotive Association for Medical and Healthcare (CPAM). This process was successfully conducted by the Vancouver Commodities Group (VCG) that had been hired by Nutra Pharma to begin the process of identifying and vetting potential distributors in China for the Company's Over-the-Counter pain drug, Nyloxin(R).

Nutra Pharma Announces Nyloxin(R) Distribution Plans for China
Marketwired - Wed Apr 22, 7:31AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have engaged the Vancouver Commodities Group (VCG) to begin the process of identifying and vetting potential distributors in China for the Company's Over-the-Counter pain drug, Nyloxin(R).

Nutra Pharma Provides Updates on Marketing and Distribution of Nyloxin(R) to India
Marketwired - Wed Apr 15, 7:30AM CDT
Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is providing an update regarding their plan to market their over-the-counter (OTC) pain reliever, Nyloxin(R) through S.Zhaveri Pharmakem for distribution throughout India. Nutra Pharma previously announced that they had shipped their initial test orders of Nyloxin(R) in February to ensure Customs clearance before escalating order sizes and frequency. Nutra Pharma management has been working in Mumbai this week to finalize their plans for the national rollout of Nyloxin.

Nutra Pharma Announces Distribution of Nyloxin(R) to India
Marketwired - Thu Feb 05, 7:30AM CST
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have shipped their initial test orders of their Over-the-Counter pain drug, Nyloxin(R), to S.Zhaveri Pharmakem for distribution throughout India.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 278

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 460

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 349

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 448

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 237

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 375

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 285

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 210

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 245

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 412

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading

Top 5 Most Recently Viewed Articles

Bain & OpenAI Enhance Collaboration for AI Solutions

Updated Category News Views 128

Bain & Co Expands AI Partnership with OpenAI Bain & Co is taking significant steps to enhance its collaboration with OpenAI, a leading name in artificial intelligence. The Boston-based consultancy has announced plans to broaden its partnership to sell various AI tools, prominently featuring ChatGPT, to its esteemed clientele. The Foundation of a Global Services Alliance...

Continue Reading
Core AI's Strategic Shift: Divesting Siyata to Enhance AI Focus

Updated Category News Views 127

Core AI Holdings Inc. Moves Forward Core AI Holdings Inc. (NASDAQ: CHAI) has recently completed a strategic divestiture of Siyata Mobile Inc. and its subsidiaries. This major decision underscores the company's commitment to refining its focus on artificial intelligence initiatives. By divesting Siyata, Core AI seeks to allocate resources more effectively towards core...

Continue Reading
Investigation into Lilium N.V. by Leading Securities Law Firm

Updated Category News Views 164

Understanding the Situation with Lilium N.V. At the heart of a recent investigation is Lilium N.V., a company that has captured significant attention in the financial markets. It has come to the forefront as Glancy Prongay & Murray LLP (“GPM”), a well-known national law firm that protects shareholder rights, takes steps to look into allegations that could reveal...

Continue Reading
Kayne Anderson Energy Fund Reports Impressive Asset Value Metrics

Updated Category News Views 233

Kayne Anderson Energy Fund Reports Key Financial Metrics Today, Kayne Anderson Energy Infrastructure Fund, Inc. (NYSE: KYN) shared its most recent financial results, highlighting its strong position in the energy sector. The report provides detailed insights into the fund's unaudited statement of assets and liabilities as of the most recent reporting period. Current...

Continue Reading
New Defense Cost Sharing Plan Between U.S. and South Korea

Updated Category News Views 138

New Defense Cost Sharing Plan Between U.S. and South Korea Recently, the United States and South Korea have solidified a new five-year agreement regarding the shared costs associated with the presence of American troops in South Korea. This collaboration highlights the ongoing commitment of both nations to bolster their defense strategies and mutual security interests....

Continue Reading